Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ef

Indication
Atopic Hand and Foot Dermatitis

Other upcoming events for LLY

Phase 2 StartPhase 2 Start: Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Ch
Phase 1 StartPhase 1 Start: A Phase 1, Single-Blinded, Single-Ascending Dose Study to Evaluate the Safety and Tolerability of a
Phase 2 StartPhase 2 Start: Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Os
Phase 3 ReadoutPhase 3 Topline: Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharm
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluatin

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ef — LLY Phase 3 Readout | BioSniper